Mylan Strikes Back At Lilly In Strattera Patent Feud
Mylan Pharmaceuticals Inc. swiped back at Eli Lilly & Co. in an infringement battle over a patent for the attention deficit hyperactivity disorder treatment Strattera, denying that Lilly's claims are valid...To view the full article, register now.
Already a subscriber? Click here to view full article